While suprapharmacologic concentrations of two SGLT2 inhibitors did reduce E0771 and MC38 tumor cell division in a cell-autonomous manner, this effect was correlated with reductions in glucose uptake and oxidation in vitro—again demonstrating the key role for dynamic regulation of tumor glucose uptake—and is likely of minimal relevance in vivo; otherwise, dapagliflozin would be expected to slow tumor growth independent of insulin replacement. This evidence concerns the gene SLC5A2 and neoplasm.